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The inadequacy of existing therapeutic tools together with the paucity of organ donors have always led medical
researchers to innovate the current treatment methods or to discover new ways to cure disease. Emergence of
cell-based therapies has provided a new framework through which it has given the human world a new hope.
Though relatively a new concept, the pace of advancement clearly reveals the significant role that stem cells will
ultimately play in the near future. However, there are numerous uncertainties that are prevailing against the present
setting of clinical trials related to stem cells: like the best route of cell administration, appropriate dosage, duration
and several other applications. A better knowledge of these factors can substantially improve the effectiveness of
disease cure or organ repair using this latest therapeutic tool. From a certain perspective, it could be argued that by
considering certain proven clinical concepts and experience from synthetic drug system, we could improve the
overall efficacy of cell-based therapies. In the past, studies on synthetic drug therapies and their clinical trials have
shown that all the aforementioned factors have critical ascendancy over its therapeutic outcomes. Therefore, based
on the knowledge gained from synthetic drug delivery systems, we hypothesize that by employing many of the
clinical approaches from synthetic drug therapies to this new regenerative therapeutic tool, the efficacy of stem
cell-based therapies can also be improved.
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Stem cell technology has generated a great deal of inter-
est in this new era of medical research due to its poten-
tial application in regenerative medicine. The two main
types of stem cells basically categorized are, embryonic
and non-embryonic cells. Embryonic stem cells (ESCs)
are derived from the inner cell mass of the blastocyst
whereas, non-embryonic stem cells, mostly adult stem
cells (mesenchymal stem cells (MSCs); multipotent stem
cells (MPCs); progenitor cells (PC) and somatic stem
cells (SSC) are specialized cells types found in various
tissues within the body [1]. Recently, another type of
non-embryonic stem cells, known as induced pluripotent
stem cell (iPSCs) was generated through enforced expres-
sion of defined transcription factors, which reset the fate
of somatic cells to an embryonic stem-cell-like state [1].* Correspondence: nhayaty@um.edu.my
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ESCs and iPSCs hamper their clinical application.
It is generally hypothesized that cell therapy using
adult stem cells hold greatest prospect of changing the
face of human diseases and alleviating suffering in the
near future. Consequently, the therapeutic potential of
adult stem cells is the main focus of scientific research;
however, in parallel, the ESCs and iPSCs have also been
proposed as promising candidates for future therapies
due to their pluripotency and personalized therapeutic
possibilities [2]. In fact, a number of useful lessons could
be learned from these two parallel cell therapy paths to
visualize the hurdles to overcome as we move forward
these therapies.
The use of stem cell therapy for many human clinical
trials is a relatively new concept in the biomedical field
[2]. Since the first successful attempts on bone marrow
transplant for treating leukemia [3], a number of similar
trials were initiated for treating several other diseases
[4-8]. After a few decades from its first demonstration ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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a promising impact to treat various degenerative and
genetic diseases including certain type of cancers [9,10],
neurological diseases [11], autoimmune diseases [12]
restoration of sight [13], wound healing [14], cardiac dis-
eases [15], liver diseases [16], metabolic disorders [17],
spinal cord injury [18] and bone disorders [19,20]. Thus,
stem cell therapy has received stunning applause from
the majority of the world population, in a hope that is
expected to cater the need for diseases treatment and
personalized medicine.
In the near future, it is anticipated that stem cell ther-
apy would surpass the conventional synthetic drug ther-
apy, which is the only treatment modality currently
available for many illness. A question still remains how-
ever: can stem cells themselves can be considered as a
biological drug? If we consider them as a drug, in fact,
both synthetic drugs and stem cells have similar purpose
in their role to cure diseases. Indeed, both therapies aim
to achieve the same goal, but they are unparallel in their
administration and clinical handlings due to their bio-
chemical properties and mechanism of action in deliver-
ing their curative effects. However, it provides better
opportunities to yield a more fruitful outcome if certain
translational clinical concepts are merged from both
therapies to formulate effective treatment strategies.
Thereby, we hypothesize that the approach in curing dis-
ease through biological means can be more beneficial if
we could adopt certain concepts of synthetic drug ther-
apies, which in turn would become decisive factors. In
fact, the current stem cell-based therapy in clinical trials
has not yet attempted many of the concepts practiced in
synthetic drug delivering systems. Nonetheless, it is an-
ticipated that by adopting some effective strategies or
procedures from synthetic drug therapy into stem cell-
based therapies, an increased efficacy of the treatment
could be expected.
Current challenges in developing effective stem cell therapy
At present, the therapeutic use of stem cells poses some
challenges because the underlying mechanism of action
of the transplanted cells are largely unknown. Indeed, a
better understanding of the properties and behaviour of
these stem cells and their mechanism of action may
open up an avenue for development of targeted therap-
ies for various diseases. In fact, some critical factors have
to be thoroughly considered before aligning and inte-
grating the stem cells with the host tissues for long term
beneficial outcomes.
Heterogeneity and inherent differential potency of
stem cells
Stem cells for therapeutic applications can be of autolo-
gous or allogeneic sources. Within our bodies theynormally reside in complex environments and constitute
heterogeneous populations [21]. Neglecting cell hetero-
geneity is one of the major causes of error in cell ther-
apy. Naturally, stem cells are programmed to divide
continuously and remain undifferentiated if the environ-
ment permits. Thus, the cells require proper signals or
cues from neighbouring cells and the microenvironment
in which the cells reside. Variations in cell to cell or cell-
environmental signalling responses can alter the func-
tional pathways of these residing cells [22]. Understand-
ing of heterogeneity and cell potency, therefore, will aid
in strategic clinical trials [23]. Hence, to interpret the in-
herent propensity of stem cells is a prerequisite to choose
the right cell for the right application and therapy.
Heterogeneity of disease progression
Another critical area that requires intense attention and is
essential to the ultimate success of cell therapies is to ex-
plore the disease progression rate for developing tailor-
made therapy with long-lasting results. This requires
detailed information about the disease especially degen-
erative disorders to offer more personalized treatment
[24]. With the advent of breakthrough in regenerative
medicine such as induced pluripotent stem cells (iPSCs),
there is an immense opportunity to revolutionize the way
human diseases are studied, especially the genetic disor-
ders. Creating iPSCs from patients with rare and common
diseases is very useful for disease modelling in providing a
platform to study the disease progression and drug devel-
opment to correct the disorder [24]. This approach could
be very advantageous in demonstrating the underlying
molecular mechanisms, as most illness are no longer con-
sidered as single disease entities but subdivided into many
factors or subtypes [25]. Given the heterogeneity and
complexity of the disease, the initial implication of stem
cell treatment could be tailored to an illness and later to
an individual context [25]. This could move therapeutic
and treatment decisions in a more systematic and target
oriented approach. Such attempts can be more or less, a
trial-and-error process at the beginning of the treatment
but could spike the clinical efficacy of this modality.
Homing and targeted stem cell delivery
Stem cells offer exquisite cell therapy due to their envir-
onment sensing cytokine receptors enabling these cells
to migrate towards gradients of chemokine secreted by
damaged tissues or tumors [26-28]. The ability of stem
cells to either passively home into tissue organs or ac-
tively home into diseased sites supports the rationale for
the targeted delivery [26]. Along with the native stem
cell homing properties, induced-homing has been
exploited for more targeted therapeutic vehicle. Much of
such targeting translation have been approached by al-
tering the cells in various ways; like substituting cell
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lipid based particles for delivering genetically modified
cells [27,29,30], use of viral vectors for gene delivery
[31-33] and use of antibody or peptide conjugated parti-
cles [27,34] based on therapeutic requirement to deliver
the cells of interest to the target sites. Despite the vari-
ous homing mechanisms, only a very small fraction of
the implanted cells migrate to desired sites, with rates of
engraftment depending on method of administration.
Accordingly, cell targeting efforts can be enhanced by ideal
physical route, utilization of physiological forces for im-
proving cell concentration, preconditioning of cells and
introduction of transgenes which can effectively activate
the cell homing process [27,32,35-37]. However, additional
efforts are still needed for better indication of the stem cell
behaviour and the target tissue microenvironments for
using such strategies singly or in combinations to deliver
the best possible therapeutics in clinical practice.
Complexity of mechanism of action of cell therapy
The key challenge in considering novel therapies is to
analyze the complex biochemical and physiological
events that occur during therapeutic implications, by
using animal models before translating such therapies to
humans [33]. Cell therapies have often been adopted
into clinical practice based on their safe and reprodu-
cible beneficial outcomes [33]. In terms of clinical prac-
tice, the basic therapeutic window is the prevention or
reversal of a disease progression. In cell-based therapy
both this approaches involves overlapping and differing
mechanisms, which should be considered for tailor-made
therapy, for disease specific clinical needs [38]. Figuring
out the various possible bio-therapeutics such as anti-
apoptotic, immunomodulation, anti-scarring, angiogen-
esis, paracrine signalling, chemo attractions and release of
supporting growth and differentiation factors for local
stem and progenitor cells is a daunting task to define the
biochemical pathways and complex inter-molecular ma-
chinery involved in cell therapy [39,40]. Embracing the
complexity of the cell, requires further research focused
on the underlying behaviour and functions as one of the
compelling requirements of cell therapy platform to im-
prove the predictive power of stem cells [40,41].
Hypothesis
Despite the success of several clinical trials using stem cell-
based therapy, there are findings reporting the failure in
treating diseases [41-45]. Infact, many questions about this
technology associated with the best cell type, suitability of
homogeneous or heterogeneous cell mixture, delivery
method, or route of administration still remains unclear or
are under intense investigations. A detail that is often over-
looked in the process of stem cell-based therapy is the
discrepancy and inadequate cell articulation in treatingmany of the ailments [46]. Perhaps, this inconsistency
might be due to the inappropriate functionalized strategies
deployed for therapeutic effects. This severely compromises
the potency of the transplanted cells, thereby, limiting their
beneficial effect. Hence, to overcome this constraint, we
propose that the efficacy of stem cell-based therapy could
be enhanced to the highest level by following some of the
basic approaches followed in synthetic drug usage. Thus,
we hypothesize that the development of strategies from
drug therapies pertaining to co-administration, mode/route,
site, doses, duration and also the preconditioning of stem
cells will allow the restoration of the functionality in in-
jured or diseased organ/tissue and also to decrease un-
anticipated clinical effects (Figure 1). This approach could
be helpful for fulfilling the potential promise of this most
exciting power of body’s own repair kit to cure diseases.
Strategies to increase the efficacy of stem cell therapy
from drug therapies
Considering the most pressing cell therapy challenges, de-
velopment of innovative pathways is highly recommended
because conventional approaches have some limitations as
far as efficacy is concerned. To address these challenges,
concepts from pharmaceutical drug research is highly
recommended to harness the power of stem cells for
improved, long-lasting outcomes. The success in pharma-
ceutical research is highly dependent on the evaluation of
the drug-disease relationship. The process of following
such relationship is attained by a series of therapeutic
interventions, which requires the identification of a broad
range of biomedical data sources. Such accumulating
evidence has led to the adoption of certain key approaches
in cell therapies from lessons learned in pharmaceutical
drug setting.
Co-administration
In clinical practices, doses or levels of therapy need to
be tuned based on the severity of the illness or other
metabolic characteristics of the patient’s underlying
condition. Employing a range of therapies could provide
physicians with the flexibility to formulate an effective
therapy which is tailor-made for the patient because it
takes into consideration the nature and stage of the
disease progression. In this regard, there is now an
increasing interest in the co-administration of drugs or
biomolecules which are often reformulated into fixed-
dose combinations [47]. The benefits are numerous; for
example, drugs can be used in lower concentration which
may diminish both the side effects and the treatment
costs. Additionally, treatments can be personalized to
individual needs [48]. Ye et al. [49] and Rosanio et al. [50]
have previously drawn attention to the benefits yielded
from the co-administration of low-dose atorvastatin drug
when combined with other agents that targeted the
Figure 1 Schematic outline of functional therapeutic approaches for stem cell based-therapy. Development of therapeutic approaches for
stem cell-based therapy in consideration of the parameters to be optimized and validated for beneficial clinical outcome. The preliminary approach of the
selection of most potential stem cell source (autologous or allogeneic) is followed by characterization for the physicochemical, biological, pharmacokinetics
and pharmacodynamics properties of these cells at in vivo and in vitro levels before clinical trials. To further enhance the therapeutic potential of these
cells at clinical trial stage, certain concepts from pharmaceutical drug therapies like preconditioning, co-administration, route of delivery, dose and
duration of treatment is to be optimized and validated for more effective outcomes. Therapeutic benefits like bioavailability, bioequivalance, targeted
delivery and dose associated disease response are to be anticipated by such clinical approaches to enhance the efficacy of the treatment.
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vascular disease. These researchers demonstrated that
co-administration of low dose atorvastatin with either
pioglitazone or sildenafil have significantly reduced the
infarct size in an animal model with myocardial ischemia-
reperfusion injury. These results demonstrated how two
different agents may act synergistically, via different
pathways to activate the same pro-survival targets.
Similarly, we are theorizing here that by co-administrating
with different types of stem cells either concurrently or in
the course of events can greatly augment the efficacy of
stem cell treatment. Our notion is supported by a previous
study where co-administration of endothelial and smooth
muscle progenitor cells of umbilical cord blood has boosted
the efficiency of vessel development in a nude mouse model
of critical hind limb ischemia [51]. Additional research alsosuggested that the combined transplantation of human
endothelial cells and mural cells have synergistically im-
proved the blood flow of nude mice of ischemic hind limbs,
remarkably, compared to the single cell type transplanta-
tions [52]. Several other studies showed the increasing
use of hematopoietic stem cell transplantation with umbi-
lical cord blood to treat malignant and non-malignant
hematologic diseases [53-57].
In light of these findings, the use of multiple cell
types, or genetically engineered cells, or combinations
of progenitor cells with cytokines, growth factors, or
even clinically proven drugs can greatly increase the
therapeutic potential. Further studies to interrogate the
molecular mechanism of these approaches would, there-
fore, give better insight for the formulation of effective
treatment.
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Pharmacological preconditioning is potentially a strong
therapeutic tool. Preconditioning has shown to be in-
volved in the protective effect from some membrano-
tropic drugs on activation of metabolic processes, thereby
improving the resistance of cell structures to various stress
factors, in particular ischemia (glycolysis, protein synthesis
and phosphorylation of membrane proteins etc.) and hyp-
oxia [58-62]. Therefore, pharmacologic preconditioning
by various types of drugs, culture conditions and physical
stimulus has opened up a new perspective to protect
organs or tissues from transplantation-associated in-
jury, thereby enhancing the success of transplantation
therapy [63]. Likewise, stem cell preconditioning and
programming by physical, chemical, genetic, biomole-
cules and pharmacological manipulation of the cells has
shown promise and “prime” the cells to the “state of
readiness” to withstand the rigors of lethal ischemia
in vitro as well as post-transplantation [64,65]. Genetic
programming, however, is considered to be unsafe due to
the introduction of foreign genetic material into cells which
could lead to tumor formation. Therefore safer reprogram-
ming and programming methods such as recombinant
protein-based or histone modification-based repro-
gramming, which provide alternative safer methods for
pre-conditioning stem cells could be an alternative. For
instance, the generation of induced pluripotent stem
cells using recombinant proteins [66] and use of val-
proic acid to induce pluripotency to amniotic fluid stem
cells is a transgene free approach [67].
One of the major challenges of stem cell transplant-
ation from bench to bedside is to maintain the cell sur-
vival hindering the manipulation of stem cells before
transplantation. This is due to the pro-apototic signals
presence in the culture environment, which acts on the
cells upon their dissociation. Preconditioned stem cells
and progenitors generally showed improved characteris-
tics such as better cell survival, increased differentiation
potential, enhanced paracrine effect, efficient homing
and integration at site of injury or diseased tissue/organ
upon transplantation [68]. Continuous effort in under-
standing the biological behaviour during manipulation
and bioprocessing of stem cells for transplantation have
led to the identification of few small molecules which
could mask the cells from apoptotic signals while har-
vesting them from monolayer. One such molecule is
ROCK inhibitor, which has been proven to enhance the
survival of the stem cells that undergo long bioproces-
sing and transplantation procedures [69,70].
Recent studies on cardiovascular diseases have also
shown that preconditioning of stem cells (bone marrow-
derived MSCs, adipose-derived stroma cells) could play
a vital role in cardio-protection and it has also enhanced
the therapeutic efficacy invariably. These studies havesuccessfully used a variety of pre-conditioners including:
transforming growth factor-alpha [71]; hypoxic condition
[72]; stromal-derived factor 1-alpha [73]; mitochondrial
reactive oxygen species [74]; trimetazidine (1-[2,3,4-
trimethoxybenzyl] piperazine [75]. Hence, preconditioning
could be suggested as a viable option for overcoming one
of the critical barriers of stem cell therapy such as the
rapid decline in viability and function of the transplanted
cells, which otherwise greatly compromise the potency of
those transplanted cells [76,77]. Nevertheless, cellular
preconditioning could enhance all the trophic mecha-
nisms (intracrine, autocrine, and paracrine signals), the
expression of survival signalling molecules, and micro-
RNAs, which could confer the cytoprotective effect [77].
Selective upregulation of survival and protective mole-
cules like hypoxia-inducible factor-1 (HIF-1), trophic/
growth factor, Protein Kinase B (PKB/AKT), focal adhe-
sion kinase (FAK), extracellular signal-regulated kinase
(ERK), glycogen synthase kinase-3ß (GSK-3ß), matrix
metalloproteinase-2 (MMP-2), survivin and Bcl-2 are
responsible for protective signalling in response to pre-
conditioning stimuli [78,79]. One of the documented
mechanisms of pharmacological preconditioning explains
the significant role of mitochondria in cytoprotection by
preventing mitochondrial permeability transition pore in-
duction [78]. This is achieved by activating mitochondrial
ATP-sensitive potassium (mitoKATP) channels by precon-
ditioning agents, which attenuates the mitochondrial Ca2+
overload thus preventing mitochondrial permeability tran-
sition pore induction. Additionally, preconditioning can
induce the upregulation of heat shock proteins, which fa-
cilitates translocation of gap junction proteins like con-
nexins Cx43, an important mediator between adjacent
cells in the form of hemichannels. Opening of Cx43 hemi-
channels helps in early communication between the trans-
planted and host cells [78,80]. This will be of great
significant factors to achieve a better communication be-
tween cells which will subsequently ease the engraftment
and functionality of the transplanted cells at target site.
Another significant element of endogenous precondi-
tioning mechanisms involves the up-regulation of stromal-
derived factor −1 (SDF-1) and CXCR4 factors which play
critical roles in mobilization, homing and engraftment of
stem cells [78,81,82]. The migration and homing efficacy
by SDF-1-CXCR4 chemotaxis is activated mainly by focal
adhesion kinase (FAK) through JAK2/STAT3 signalling
[78]. Alternatively, P13K/Akt/eNOS signalling also have
been reported to trigger the SDF-1 mediated migration
of stem cells [78], in which these signalling pathways
also play a major role in proliferation and survival of
cells. Though found effective, still many of the tissue
engineering studies haven’t explored the potentiality of
pre-conditioning. Therefore, we emphasise that treating
the cells with exogenous agents such as conventional
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signalling molecules during ex vivo expansion before
transplantation could greatly increase the efficacy of
stem cell therapy.
Route of transfusion
Whenever new methods or routes are introduced for
synthetic drug administration, it becomes vitally import-
ant to gain better insight into their pharmacokinetics
and pharmacodynamic implications [83]. For any drug
to exert its pharmacological effect, it must first gain its
entry into the body, followed by absorption into the
blood stream, which finally transports or distributes
them to its target of action. However, certain factors are
found to influence the process of drug absorption and
restrict the efficacy of treatment. These include the
physicochemical properties of the drug which determine
transfer across cell membranes, formulation or physical
state of the drug, site of absorption, circulation at ab-
sorption site and area of absorbing surface [83]. Absorp-
tion site or the port of entry, the speed, ease, and degree
of absorption are determined by the route of drug ad-
ministration [83].
Similarly, a better understanding on the route of ad-
ministration for efficient viable cell delivery becomes a
necessity for stem cell therapies [84,85]. However, little
is known regarding the optimal delivery strategy for
stem cells due to the inadequacy of the tools to label
and track those transplanted cells. To date, depending
on the patient condition, a variety of stem cell delivery
options have been adopted based on preclinical and clinical
studies for repairing different tissues like cardiac tissue
(intracoronarily, intramyocardial, catheter-based injections)
[86-90]; brain (intracranial, intravenous, intranasal, cir-
culatory systems) [91-93] and spinal cord (intra-arterial,
intravenous; cerebrospinal fluid by lumbar puncture)
[94,95]. However, several studies have revealed that route
of stem cell (MSCs) administration near to the target site
have shown more potential than the other routes of ad-
ministration [96-99]. In some other studies multiple route
delivery technique has shown substantial advantage over
the single route administrating techniques, to ensure the
cell homing to the target area to promote tissue repair
[100]. Although, the complexity of multiple route delivery
limits the mechanistic understanding of cell- based appli-
cations, the feasibility of safe and assured delivery to the
target niche ensures the endogenous repair which is
greatly demanding criterion, due to heterogeneity of hu-
man injuries. Hence, for the success of any stem cell ther-
apy, we suggest that finding the right route for cell
administration is of prime importance. This is only achiev-
able by understanding the migratory property of these
cells and the cell behaviour along the migratory route.
Moreover, it has to be made sure that the transplantedcells are not homing, other than the area of interest of
organ repair, otherwise it could lead to disturbance of nor-
mal homeostasis in the function and regulation of other
organs [57]. Therefore, we propose that the approach of
stem cell therapy should be basically target specific and
the cell administration to achieve this target specificity
[101]. Thus, developing tools to label and track those
transplanted cells, prime the cells to adopt the migration
potential and co-administrate factors to effectively induce
the repopulation of integrated stem cells would be of great
benefit to make cell therapy a success.
Treatment modalities: doses and duration
Every patient has a unique therapeutic threshold for
each prescribed drug due to individual drug sensitivities
[102,103]. Age and gender, are two other significant fac-
tors which influence the pharmacokinetics and pharma-
codynamics of a drug [104,105]. Hughes and Aronson
[106] defined that duration of action of a drug is directly
proportional to the logarithm of dose for a wide range of
different drugs, revealing the significant role played by
both these variables on the treatment outcomes. There-
fore, when drugs are administrated, a meticulous under-
standing of the dose–response relationship is of great
significance for achieving the specific therapeutic effect
while minimizing their side-effects [107,108]. Generally
for stem cell based treatment, a 70 kg-patient needs ap-
proximately 2 × 106 MSCs per kilogram body weight for
transplantation [109]. However, reports suggest that
there are variations in optimal or effective doses re-
quired for various diseases, albeit the source of the stem
cells is the same. For examples, 3–5 × 107 cell/kg ex-
vivo expanded autologous bone marrow derived mesen-
chymal stem cells (BM-MSCs) were administrated into
each patient with multiple sclerosis [110] whereas in
spinal cord injury, 5–6 × 106 cells/kg were transplanted
[111]. Liang et al. [112] reported that a dose of 1 × 106
cells/kg allogeneic bone marrow MSCs were transplanted
via intravenous infusion through a single administration for
treating refractory systemic lupus erythematosus. Clinical
trials for graft-versus-host disease (GVHD) using allogeneic
MSCs (adipose derived stem cells, bone-marrow derived
MSCs, hematopoietic stem cell, peripheral blood stem cell,
Prochymal) demonstrated beneficial responses in both
pediatric and adult patients when infused (single to mul-
tiple times) with different doses based on severity of the
disease [1]. Similar studies of dose escalation phase I clinical
trial using different doses of allogeneic MSCs (Prochymal)
ranging from 0.5, 1.6, and 5 million cells/kg in patients with
myocardial infarction showed safety efficacy data [113]. An
overall assessment of the patient health was evaluated dur-
ing the course of trial for signs of improvement or deterior-
ation. Significantly, when analyzed for dose-dependent
effects, patients exhibited dose responsiveness in terms of
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did not differ in the control and low dose treatment groups,
but variation was evident in the mid and high dose treat-
ment groups. In yet another pilot study, phase I/II clinical
trials was conducted for demonstrating the efficacy of allo-
geneic bone marrow derived MSCs in patients with chronic
ishemic cardiomyopathy (ICM) [114]. Currently, phase
I clinical trial is being conducted on dose escalation
study of autologous MSCs in patients with Amyo-
trophic Lateral Sclerosis for determining the dose limiting
toxicities [115,116]. In another study, dose escalation
Phase 2 clinical trial of MultiStem (allogenic cell therapy
treatment comprising of multipotent adherent bone mar-
row cells) in patients with ischemic stroke was measured
with two dose tiers of 400 million and 1200 million cells
per patient to determine the highest well-tolerated and
safe single dose of multistem [117]. Further clinical trials
are being conducted for dose-escalating therapeutic study
of allogeneic bone marrow derived mesenchymal stem
cells for the treatment of fistulas in patients with refrac-
tory perianal crohn’s disease [118].
While study results provide assurance for the safety of
allogeneic human mesenchymal stem cells (hMSCs),
further work is in demand to delineate the mechanism of
action of this MSC therapy in dose responsiveness manner.
In addition, other factors such as source of stem cells, their
functionality level, disease stage and route of administra-
tion, niche microenvironment can also influence the
dosage and duration of stem cell therapy for a particular
disease. For example, studies have reported poor engraft-
ment of transplanted stem cells which could be due to
impaired target niche microenvironment after intensive
chemoradiotherapy or lower doses of cell infusion [57].
Hence, development of dose-intensive delivery programs
can possibly improve the response rates and outcome of
treatment. Further evaluation of the efficacy in terms of
safety and functional outcome of repeated dose/duration
period can result in major advance in stem cell treatment
strategies when compared to conventional therapy.
Although, promising results have been highlighted using
MSCs in clinical trials, the underlying dose and follow up
dose associated mechanisms still remains unclear. Never-
theless, studies involving MSC therapy demonstrates a clear
involvement of intricate mechanism of migration, homing
efficiency, immunological properties, differentiation and
secretions of bioactive molecules in an integrative manner.
Taking all these notes together, it is possible that dose asso-
ciated potential efficacy of allogeneic/autologous stem cells
with single or repeated infusions can translate significant
changes in clinical aspects. Further, it is plausible to
propose that treating a disease with terminally differenti-
ated cells would require higher cell number than by pro-
genitors because the latter option provides the opportunity
for this cell to proliferate and produce a larger mass andmay differ in its secretions of bioactive molecules to substi-
tute or repair the lost functional tissue. However, the
unique tropism of cell therapy has to be taken into account
for the optimization of cell infusion doses and duration to
prevent cell losses for an effective transplantation setting.
Taking all these issues together, stem cell therapy has a
great potential to evolve further answers to the challenges
associated with cell therapy transplantations as to ensure
reproducible personalized therapy (Figure 2).
Therapeutic road map differ between autologous or
allogeneic (off the shelf) cell products
Globally there are between 300 to 700 companies, ranging
from small university spinouts to multinational corpora-
tions involved in developing cell-based therapy such as
GlaxoSmithKline, Johnson & Johnson, Pfizer, and Sanofi
(Genzyme) [119]. Persistent development of cell-based
therapy research and development (R&D) industrial
players in stock market index suggests the demand and
potential of this industry as a distinct healthcare sector
(119) Table 1. Clinical transplantation mostly set to
utilize allogeneic or syngeneic (genetically similar) donor
cells due to the complications/difficulties in extracting or
obtaining ample patient-derived cells. One main reason
for this phenomenon is that aging and disease pathophysi-
ology affect the number and functional properties of stem
cells in patients [3,120]. Besides, allogeneic cells can be
readily isolated from healthy donors and thus can be used
as an “off-the-shelf” biological reagent. Furthermore, pre-
cultured human stem cells offer an improved practicality
in consideration for cell therapy than compared with
on-site isolated autologous cells. Firstly, the homing ability
of allogeneic MSCs to injured site or tissue could be well
stimulated during culture by manipulating the expression
of SDF-1/CXCL12 axis, which in turn induces the migra-
tory ability [113]. Second, the lack of various major
histocompatibility complexes (MHC) and co-stimulatory
cell-surface antigens makes them a perfect allogeneic
graft, additionally having the conferred anti-inflammatory
properties [113]. For instance, the host immune system
cannot detect the donor MSCs (allogenic graft) on ac-
count of low levels of human leukocyte antigens (HLA)
present on surface of these cells [1]. Third, it offers an
enriched population of therapeutically relevant cells, as
demonstrated in various pre-clinical studies [113]. Finally,
the differentiation potential of stem cells into tissue
specific cells of different lineages is advantageous [1].
Although the differentiation potential of embryonic stem
(ES) cells is greater than of somatic stem cells, studies have
proven that MSCs can be conferred into more pluripotent
state by epigenetic modification which facilitates an effi-
cient differentiation into cells of different lineages [1].
Hence, this approach makes MSCs suitable for the treat-
ment of various disease pathologies and injuries.
Figure 2 Model stem cell transplantation process for effective personalized application. An overview of stem cell transplantation model
tailored-made for a personalized therapy, with ideal culture conditions to be optimized at bio-processing and transplantation procedures to
enhance the viability, migration and homing properties of the transplanted cells for achieving the best possible effective personalized therapy.
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http://www.translational-medicine.com/content/12/1/243In some instances, there are studies addressing the safety
concerns associated with the preparation of allogeneic cells,
which showed a detectable level of HLA once they are inte-
grated and differentiated in the host. This leads to the graft
rejection and chronic immune responses [141]. Therefore,
issue over such graft rejection even when the cells expresses
HLA at low level, in turn makes the autologous and mini-
mally in vitro manipulated cells as an attractive and promis-
ing curative bio-reagents for many regenerative, anti-
inflammatory and autoimmune related diseases. Indeed,
studies have revealed the suitability of both autologous and
allogeneic culture-expanded MSCs in cardiovascular stud-
ies [114], in which direct myocardial injection of autologous
expanded BM-MSCs was found to show significant effect
in structural and functional measures for ischemic Left
Ventricular dysfunction [142]. While the attempt to utilize
the autologous MSC to achieve individual treatment has
been the focus for the past few decades, application of these
cells through fibrin spray or in the form of conditioned
media (culture media of MSCs consisting of cell secretions)are also under investigation for treatments like wound
repair, burns and other soft and connective tissue repair
[143-145]. Having said this, factors such as nature of the
disease, type of stem cells and patient condition need to be
taken into consideration before formulating an effective
procedures and approach to utilise autologous and allo-
geneic cell-based therapy (Figure 3).
A great new venture in which the cell therapy based
industry moving towards is the generation of patient
specific induced-pluripotent stem cells (iPSCs), bringing a
whole new dimension in developing cell based therapy to
the next level moving this endeavour from bench to bed-
side application. Various aspect of biological properties and
therapeutic models are under investigation in order to
develop such patient specific stem cells. Although, a recent
study has reported limited immunogenicity of transplanted
cells differentiated from iPSCs and embryonic stem cells
[146], the immunological barriers of patient specific- cell
transplantation are the same as those encountered and
continue to confound for allogeneic cells. Indeed, long
t-
Table 1 Stem cell therapy companies and their cell products in development
Company name Cell types Therapeutic programs/product name Clinical a Reference
Aastrom Bioscience Autologous Multicellular therapy
(Ixmyelocel-T)
Cardiova ar disease [121]
Periphera tery Diseases (PAD)
Cytomedix Autologous adult stem cells ALDHbr (autologous regenerative cell therapy utilizing
proprietary ALDH Bright Cell technology to isolate
biologically active pluri-potent stem cells for therapeutic use)
Ischemic rt failure [122]
Ischemic ke
Critical lim ischemia
Periphera tery Diseases (PAD)
Cytori Therapeutics Autologous adult adipose derived
stem cells
Celution 800/CRS system (The system automates and
standardizes the extraction and concentration of patients
own Adipose Derived Regenerative Cells (ADRCs) in a clinical











Dendreon Autologous cellular immunotherapy Provenge (sipuleucel-T) Body’s own immune cells are





Fibrocell Science Autologous Fibroblasts Azficel-T s BLA Program Skin [125]
Intrexon Synthetic Biology Rare Disease Program
(Autologous cellular product treat rare and serious skin




Autologous dendritic cell ICT- 107 (newly diagnosed Glioblastoma) Glioblast multiforme [126]
ICT- 121 (Recurrent Glioblastoma) Ovarian c er
ICT- 140 (Ovarian cancer) Cancer s cells
Autologous dendritic cell based vaccines
Japan Tissue Engineering
Company (J-TEC)
Autologous cell Autologous cultured epidermis Burns [127]
Autologous cultured Cartilage Cartilage ects
Autologous cultured Corneal Epithelium

















































Table 1 Stem cell therapy companies and their cell products in development (Continued)
Advanced Cell
Technology
Allogeneic adult stem cells hESC-derived
cells
Retinal Pigment Epithelial Cell Program for:
Stargardt’s macular dystropy (SMD)
Retinal D nerative Conditions [130]
Dry Age-Related Macular Degeneration (AMD) Blood an rdiovascular diseases
Hemangioblast (HG) Program for: Diseases and disorders
of circulatory and vascular system





BioTime Clinical-grade human embryonic stem
(hES) cell lines
OpRegen (hESC-derived RPE cells for the treatment of
macular degeneration)
Age-rela degenerative disease [132]
OPC1 (hESC-derived oligodendrocyte progenitors for
spinal cord injury);
Spinal co njury
VAC1 (a dendritic cell-based vaccine for cancer based
on the telomerase antigen)
Neurosci e orthopedics blood and vascular
diseases ology
Medipost Allogeneic human umbilical cord blood
and Umbilical Cord Blood derived
Mesenchymal Stem Cells (hUCB-MSCs)
Cartistem (cartilage defect) Cartilage ects [133]
Neurostem (neuro-degenerative disorders) Alzheime isease
Pneumostem (pulmonary disorders) Amyotro Lateral Sclerosis (ALS)
Promostem (early engraftment of donor hematopoietic
stem cells (HSCs))
Stroke
Chronic disease (premature babies)
Mesoblast Allogeneic adult derived mesenchymal
precursor cells (MPCs)
Proprietary Mesenchymal stem cells lineage technology Systemic eases with underlying inflammatory
and imm logic etiology
[134]
Mesenchymal stem cells (MSCs) Cardiac a vascular diseases
Dental pulp stem cells (DPSCs) Orthope iseases of spine
Hematopoietic stem cells (HSCs) Improvin utcome of bone marrow
transplan on
Neostem Autologous adult stem cells, Targeted Immuno Therapy Program Cancer t ent [135]
Allogeneic T cell Embryonic like stem cells
& Progenitor Cells
CD34 cell program Ischemic air
T Regulatory Cell Program Immune dulation
VSEL (Very small embryonic like stem cells ) technology Tissue re eration
NeuralStem Human hippocampus Neural Stem cells NSI-189 (a compound developed for oral administration for
psychiatric and cognitive disorders)














































Table 1 Stem cell therapy companies and their cell products in development (Continued)
Osiris Therapeutics Autologous and Allogeneic Mesenchymal
stem cells (MSCs)
OvationOS (bone matrix designed for the filling of bony voids
and to support bone repair and regeneration)
Bone damage [137]
Soft tissues(cartilage and tendon) wound healing
Grafix (Allogeneic MSCs in extracellular matrix)
Cartiform (3-dimensional architecture of hyaline cartilage that
contains the necessary cellular and molecular components for
articular cartilage repair, and is primed for mesenchymal stem
cell (MSC) activity)
Pluristem therapeutics Allogeneic cells PLX (Placental expanded cells) Cardiovascular disease [138]
Orthopedic disease
Pulmonary diseases
Stemcells Allogeneic tissue derived adult stem cells
and progenitor cells
HuCNS-SC (human neural stem cells) Spinal cord injury [139]
hLEC (human liver engrafting cells) Peripheral artery Diseases (PAD)
Pelizaeus-Merzbacher Disease (PMD)
Age-related macular degeneration (AMD)
Tigenix Autologous and Allogeneic adult stem
cells
ChondroCelect (Autologous Chondrocytes) Cartilage defects [140]




















Figure 3 Road map for allogeneic and autologous “off-the-shelf” cell products for therapeutic applications. Road map for allogeneic and
autologous “off-the-shelf” cell products for stem cell transplantation. Isolated cells can be used for the cell therapy with or without the manipulation of
the cells for enhancing the potentiality or differentiate them into desired cell types before the transplantation. These cells could be stored for the
future personalized medical applications. The cell transplantation approaches can vary from systemic and injection to topical application or with
scaffold depending on the treatment requirement of the patient. Finally the stem cell transplanted patients should be followed-up of analyzing the
disease recovery and treatment effectivity.
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structure, genetic manipulation and epigenetic reprogram-
ming can impair immune privilege status of the autologous
and allogeneic cells [147]. Accordingly, in such safe person-
alized regenerative stem cell therapy scenarios, the selec-
tion of the least incompatible stem cells, safe generation of
stable and clinical grade iPSCs lines in xeno-free and fully
defined culture conditions and proper characterization of
quality parameters to ensure cell purity and potency along
with the host MHC information is to be considered to
avoid or attenuate the host immune response to the trans-
planted stem cells [147,148].
Another approach would be the development of HLA-
matched cell banks, which are the focus of stem cell bio-
bank services provided by some of the healthcare indus-
trial players [119]. Considering the surrounding merits of
using autologous and allogeneic stem cells, it might befurther insightful to gain beneficial information on the im-
munogenetics by direct comparison between both these
cell types and iPSCs and iPSC-derived therapeutically rele-
vant cells to control and ensure successful therapeutic im-
pact upon transplantations. Thus, the use of “off the shelf
cell products” is highly attractive in their point-of-care in
cell therapeutics. Hence, by ensuring the continued devel-
opment of the regulatory framework, therapeutics inter-
ventions and other supportive technologies by healthcare
bodies and industries, it will accelerate this exciting new
therapeutic venture and bring impact to the future suc-
cesses of the cell therapy industry.
Pharmaceutical drug therapeutic lessons translatable and
not translatable to stem cell therapies
Both synthetic and natural drugs are generally well-
characterized of their formulation, biochemical reactions,
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end and by-products. On the other hand, the significant
limitations to the development of stem cell therapy for pa-
tients includes; a) the lack of knowledge on the active cel-
lular constituent of stem cells that are responsible for the
reparative action b) the possibility that therapeutically ac-
tive cells may represent only a very small fraction of the
total stem cell population and, c) their potential to differ-
entiate into variety of cell lineages govern by the in vivo
microenvironment factors. Mostly, pharmaceutical treat-
ments deliver a single agent at a specific dose to either
catalyse or inhibit the biochemical reactions. On the other
hand, stem cells are site-regulated and they are capable to
secrete bioactive factors and give signals at variable con-
centrations in response to local microenvironmental cues
[141]. Thus, while designing cell therapy, the criteria,
measurement and outcome one would expect for an opti-
mal combination to specific organs or disease could most
likely be variable because of the complexity of the parame-
ters. Hence, understanding the complexity represented by
the behaviour and responses of these stem cells requires
the development of novel approaches and strategies which
are not present in drug therapy and yet to be developed.
Albeit therapies based on drugs and stem cells have to

























Local or systemic Targete
Intracranial, intranasal, circulatory system Better
integra
transplIntra-arterial, intra venous, cerebrospinal
fluid by lumbar puncture
Doses & Durations
Cell dose based on MSCs sources Minimi
by fixe
Single or multiple infusion Prevenconcepts of drugs therapies like the pharmacogenomics
will be of high importance in developing cell therapies.
In pharmacogenomics, it has been hypothesized that hu-
man genetic variations could dictate the efficacy and
toxicity of drugs [149]. Thus the genetic information can
be utilized to predict the safety, toxicity and/or efficacy
of drugs. Accordingly, pharmacogenomics studies are
mostly carried out through candidate gene approach and
prior knowledge of the drug mechanism. Specific genes
that encode for drug metabolizing enzymes, drug trans-
porters and drug related proteins are also considered for
screening before treatment. Similarly, cell secretions
have a role in an individual’s genotype expression [120].
Equivalently, to commensurate the cell therapeutic
mechanism for such response reaction could be analysed
for the genes of interest and also other relevant genes in-
volved. For instance, those genes involved in the im-
mune response could be used. Thus, the concept of
utilizing the role of human genetic variation to such re-
sponsive agents (either stem cells or drugs), provide cre-
dence to the concept of personalized medicine.
To better understand these factors and to optimize the
beneficial effect of these therapies, it is important to
monitor the clinical trials and the outcomes. While the
best treatment strategy either by employing conventionalapeutic procedure
ts/outcomes Problems to be addressed
ion of cell
geneity
Utilization of correct combinations
ing cell signalling
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Understanding cell signalling for effective cell
formulations
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considerations, in other situations research investigating
the psychosocial experience and quality of life of patients
undergoing such treatments should also be considered.
Clearly, the beneficial effect of these therapies must be
weighed against the risks, but experimental studies must
be encouraged to design combinational procedures by
exploring newly developed concepts and protocols.
Future perspective of stem cell therapy in regenerative
medicine
Regenerative medicine and cell therapy are poised to
have a tremendous impact on the future of medicine by
delivering more effective, long-lasting, safe and cost-
effective therapies for life- threatening and life-altering
conditions than are currently available today. The extent
to which we are able to achieve effective cell therapies
will depend on assimilating a rapidly developing base of
scientific knowledge with the practical considerations of
design, delivery, and host response. Hence, a continuous
effort is required to achieve a refined application of stem
cell therapy to expand the role of stem cells for their
vanguard uses. Table 2 details the cell therapy strategies,
benefits and current challenges to be refined for more
effective stem cell therapeutic procedure.
Conclusion
This hypothesis is aimed to propose the possible mimick-
ing or recapitulation of certain clinical approaches from
conventional drug therapy to stem cell-based therapy to
improve their efficacy. Adopting such approaches will give
immense value in translating stem cell therapy from bench
to bedside. In addition to satisfying the scientific basis of
stem cell treatments, this approach will bring about viable
options to overcome current limitations in stem cell ther-
apy. Implication of this approach in stem cell therapy is ex-
pected to not only modulate the outcome of intended
therapy, but also will be a feasible option for the cost ef-
fectiveness of stem cell-based regenerative therapies in the
near future. Therefore we suggest that the stem cells ther-
apy should be also be seen from the point of view drug.
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